Table 3.
Risk Factors for Meropenem-nonsusceptibility Among Pseudomonas aeruginosa Bloodstream Isolates
| Risk Factor | MPM NS (n = 30) | MPM S (n = 25) | P Value | OR (95% CI) |
|---|---|---|---|---|
| Gender | ||||
| Male | 21 | 16 | 0.6 | 1.3 (0.4–4.1) |
| Female | 9 | 9 | ||
| Age, median (range) | 61 (22–73) | 63 (21–80) | 0.5 | ND |
| FQ breakthrough | ||||
| Yes | 22 (73.3) | 4 (16) | <.0001 | 14.4 (4.1–62) |
| No | 8 (26.7) | 21 (84) | ||
| HCT recipient | ||||
| Yes | 17 (56.6) | 12 (48) | 0.5 | 1.4 (0.5–4.3) |
| No | 13 (43.4) | 13 (52) | ||
| Neutropenia | ||||
| Yes | 22 (73.3) | 16 (64) | 0.5 | 1.5 (0.5–5) |
| No | 8 (26.7) | 9 (36) | ||
| CP exposurea | ||||
| Yes | 6 (20) | 4 (16) | 0.7 | 1.2 (0.3–5.5) |
| No | 24 (80) | 21 (84) | ||
| Antipseudomonal β-lactam exposurea,b | ||||
| Yes | 15 (50) | 9 (36) | 0.3 | 1.8 (0.6–5.4) |
| No | 15 (50) | 16 (64) | ||
| Hospital-associated infectionc | ||||
| Yes | 27 (90) | 15 (60) | 0.01 | 6 (1.6–30) |
| No | 3 (10) | 10 (40) | ||
| ICU stayd | ||||
| Yes | 3 (10) | 1 (4) | 0.6 | 2.7 (0.3–27.4) |
| No | 27 (90) | 24 (96) | ||
Abbreviations: CI, confidence interval; CP, carbapenem; FQ, fluoroquinolone; HCT, hematopoietic cell transplant; ICU, intensive care unit; MPM, meropenem; ND, not determined; NS, nonsusceptible; OHSU, Oregon Health and Science University; OR, odds ratio; S, susceptible.
aMeasured as ≥1 dose within 90 days of bacteremia.
bIncludes ceftazidime, cefepime, and piperacillin-tazobactam.
cDefined as an infection occuring ≥3 days following OHSU admission or ≤14 days after OHSU discharge.
dAt least 24 hours in a medical or surgical ICU within 90 days prior to bacteremic episode.